You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海醫藥(02607.HK):與軒竹生物就百納培南項目、Plazomicin項目進行合作
格隆匯 06-16 17:37

格隆匯6月16日丨上海醫藥(02607.HK)公佈,近日,公司控股子公司上海上藥新亞藥業有限公司(以下簡稱"上藥新亞")分別與軒竹生物科技股份有限公司(以下簡稱"軒竹生物")、軒竹(北京)醫藥科技有限公司(以下簡稱"軒竹北京")簽訂了《授權許可協議》,以不超過人民幣(幣種下同)2.66億、1.74億(均除銷售提成外)的交易對價取得百納培南項目、Plazomicin項目(均含原料藥和製劑,下稱"許可產品")在中國區域的獨佔許可,包括再許可、使用、生產、進口、開發、包裝、分銷、銷售等一切權利。上藥新亞或其指定的機構將成為許可產品在授權區域內獨家的上市許可持有人。上藥新亞將擁有自行或通過委託研發等形式開發的與許可產品相關的一切新專利的所有權。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account